Annexon (ANNX) announced that it has commenced an underwritten public offering of $75M of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. Goldman Sachs & Co., TD Cowen and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating
- Positive Investment Outlook for Annexon Biosciences Driven by Financial Stability and Key Pipeline Developments
- Annexon Biosciences Reports Increased R&D Expenses
- Annexon reports Q3 EPS (37c), consensus (34c)
- ANNX Upcoming Earnings Report: What to Expect?